Introduction
The global healthcare sector is entering a period of fundamental transformation. Driven by demographic shifts, technological innovation and changing consumer expectations, healthcare is evolving from reactive treatment to preventive, data‑driven and personalised care.
The Future Health theme captures the long‑term investment opportunities arising from this transformation across biotechnology, digital health, medical technology and life sciences.
The pillars of Future Health
Biotechnology & genomics
Advances in genetic sequencing and synthetic biology enable targeted therapies and personalised medicine, supporting more effective and efficient treatments.
Digital & remote health
Telemedicine, wearable devices and mobile health applications allow patients to monitor their health and access care remotely, reducing pressure on healthcare systems.
Artificial intelligence & data analytics
AI enhances diagnostics, treatment planning and predictive healthcare by analysing medical images, patient records and real‑time biosignals.
Preventive & lifestyle medicine
A growing focus on prevention through nutrition, exercise and behavioural science aims to reduce chronic disease and long‑term healthcare costs.
Let’s take a closer look at Future Health
Discover how structural trends such as demographic change, technological innovation and preventive care are reshaping healthcare systems worldwide.
Download our Future Health brochure to explore the investment case, key drivers and opportunities across the healthcare ecosystem.
Future Health focuses on innovations that improve healthcare outcomes through technology, data and preventive approaches, moving beyond traditional treatment models.
Ageing populations are fuelling sustained demand for healthcare, chronic disease management and assisted‑living technologies. At the same time, technological advancements in biotechnology and artificial intelligence are accelerating drug development and enabling innovative treatments.
Technology supports faster diagnosis, personalised treatments and more efficient healthcare systems through AI, data analytics, digital platforms and connected devices.
Preventive and lifestyle medicine aims to reduce chronic disease by focusing on early detection, nutrition, exercise and behavioural science.
The sector faces challenges such as data privacy, complex regulations, ethical issues related to gene editing and artificial intelligence, and ensuring fair access to new treatments.
The convergence of biotechnology, data science and preventive care is reshaping healthcare systems worldwide.
Alexandra Spasov – Funds Solution Analyst & Thematic Research
Download our Guide
Future Health represents a defining long‑term opportunity. By investing across biotechnology, digital health, medical technology and pharmaceuticals, portfolios can gain exposure to both defensive stability and structural growth.
IMPORTANT INFORMATION
Information correct as of April 2026.
-
Investing puts your capital at risk.
This document is designed as marketing material. This document has been composed by Brown Shipley & Co Ltd (“Brown Shipley”). Brown Shipley
is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Registered in England and Wales No. 398426. Registered Office: 2 Moorgate, London, EC2R 6AG.
This document is for information purposes only, does not constitute individual (investment or tax) advice and investment decisions must not be based merely on this document. Whenever this document mentions a product, service or advice, it should be considered only as an indication or summary and cannot be seen as complete or fully accurate. All (investment or tax) decisions based on this information are for your own expense and for your own risk. You should (have) assess(ed) whether the product or service is suitable for your situation. Brown Shipley and its employees cannot be held liable for any loss or damage arising out of the use of (any part of) this document.
The contents of this document are based on publicly available information and/or sources which we deem trustworthy. Although reasonable care has been employed to publish data and information as truthfully and correctly as possible, we cannot accept any liability for the contents of this document, as far as it is based on those sources.
Investing involves risks and the value of investments may go up or down. Past performance is no indication of future performance. Currency fluctuations may influence your returns.
The information included is subject to change and Brown Shipley has no obligation after the date of publication of the text to update or amend the
information accordingly. Accordingly, this material may have already been updated, modified, amended and/or supplemented by the time you receive or access it.
This is non-independent research and it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
All copyrights and trademarks regarding this document are held by Brown Shipley, unless expressly stated otherwise. You are not allowed to copy, duplicate in any form or redistribute or use in any way the contents of this document, completely or partially, without the prior explicit and written
approval of Brown Shipley. Notwithstanding anything herein to the contrary, and except as required to enable compliance with applicable securities law. See the privacy notice on our website for how your personal data is used (https://brownshipley.com/engb/privacy-and-cookie-policy).